Breaking News

Aurobindo To Acquire Actavis' Generics Infrastructure

By Kristin Brooks | January 20, 2014

Includes operations in seven markets in Western Europe

Actavis has entered an agreement with Aurobindo Pharma Ltd. under which Aurobindo would acquire Actavis' generic commercial operations in France, Italy, Spain, Portugal, Belgium, Germany and the Netherlands, including products, marketing authorizations and license rights. The two companies would also enter into a long-term strategic supply agreement.The transaction is subject to certain antitrust approvals and completion of employee consultation processes.
The acquisition would creates one of the largest Indian generic pharmaceutical companies in Europe and expands Aurobindo’s existing European operations with additional capabilities in seven countries, and includes brands such as Arrow Generiques.

"We believe that the value created by the commercial operations in these seven markets will be better maximized by Aurobindo, which will gain scale, additional products and enhanced competitive market share position as a result of this transaction," said Sigurdur Oli Olafsson, president, Actavis Pharma. "This transaction will permit Actavis to focus management time and resources to support accelerated investment in driving faster growth of other markets, including Central and Eastern Europe and Southeast Asia."
Until the transaction is completed, Actavis will continue to operate the commercial businesses.
Rothschild and Latham & Watkins acted as financial adviser and legal counsel to Actavis, respectively. Jefferies International acted as financial advisor and Herbert Smith Freehills LLP as legal counsel to Aurobindo.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks